Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Rabia Altintas"'
Autor:
Muhammad Murtaza Hassan, Yasir S. Raouf, Pimyupa Manaswiyoungkul, Aaron D. Cabral, Abootaleb Sedighi, Rabia Altintas, Fettah Erdogan, Patrick T. Gunning, Giovanni Ganda, David W.J. Armstrong, Olasunkanmi O. Olaoye, Elvin D. de Araujo, Johan Israelian, Fabrizio Angeles, Nabanita Nawar
Publikováno v:
Journal of medicinal chemistry. 63(15)
Histone deacetylases (HDACs) are an attractive therapeutic target for a variety of human diseases. Currently, all four FDA-approved HDAC-targeting drugs are nonselective, pan-HDAC inhibitors, exhibiting adverse side effects at therapeutic doses. Alth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456714751dd802b91d1d0aa5585e2945
https://pubmed.ncbi.nlm.nih.gov/32672458
https://pubmed.ncbi.nlm.nih.gov/32672458
Autor:
Niklas Jänsch, Rabia Altintas, Benjamin Wolff, Maraike Lang, Franz-Josef Meyer-Almes, Stefan Frühschulz, Wisely Oki Sugiarto, Ina Oehme
Publikováno v:
European journal of medicinal chemistry. 184
Human histone deacetylase 8 (HDAC8) is a highly promising target for neuroblastoma and other types of cancer. Several HDAC inhibitors are approved for the treatment of special cancer subtypes or are evaluated in clinical trials. By far the most drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95cf34f0c7bff44a15eddbdf25902ba8
https://pubmed.ncbi.nlm.nih.gov/31630054
https://pubmed.ncbi.nlm.nih.gov/31630054